Helpless—but not unhelped! While he sleeps the unceasing search goes on for new or better antigens to protect him from infectious diseases once regarded as unavoidable hazards. Take whooping cough, the world’s No. 1 killing disease of babies in the first year of life. By perfecting precise methods of making and testing pertussis vaccines Glaxo research has materially helped to raise whooping cough immunisation to its present high level of effectiveness. Significantly, it was Glaxo workers who were asked to assist in the preparation of the British Standard Pertussis Vaccine which was subsequently accepted as the International Standard. Every batch of Whooping Cough Vaccine Glaxo (and combined antigens containing it) measures up to these same high standards.

The primary immunising course with Whooping Cough Vaccine Glaxo is three 1 ml injections (or three ½ ml injections if the Glaxo half-volume vaccine is used); the first injection should be given at not later than three months of age.

GLAXO PRODUCTS FOR PROTECTION

The following vaccines are available in two concentrations, which provide a full dose of antigen in either 1 ml (standard vaccine) or 0·5 ml (half-volume vaccine)

WHOOPING COUGH VACCINE
TRIPLE ANTIGEN
(Diphtheria-Tetanus-Pertussis Vaccine)
DIPHTHERIA-PERTUSSIS PROPHYLACTIC
TETANUS TOXOID
PERTUSSIS-TETANUS PROPHYLACTIC
DIPHTHERIA-TETANUS PROPHYLACTIC

The products below are available in standard dilutions only

DIPHTHERIA PROPHYLACTIC (Formol Toxoid)
*POLIVIRIN (poliomyelitis vaccine)
Freeze-dried B.C.G. VACCINE
*INVIRIN (bivalent influenza vaccine)
STAPHYLOCOCCUS-TOXOID

*Trade marks